Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant with renal failure.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 1432439.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We treated an infant with anemia and chronic renal failure with recombinant human erythropoietin (300 to 750 U/kg subcutaneously per week) and iron (6 mg/kg enterally) from 1 to 4 months of age. A suboptimal pharmacodynamic response was seen at the lower dose. This may have been due to developmental erythropoietin pharmacokinetic differences, that is, relatively greater neonatal plasma clearance and steady-state volume of distribution compared with those in adults.
Medical subject headings
- Erythropoietin
- Kidney Failure, Chronic